South Korean Won: Uptrend seen resuming against US Dollar – Societe Generale
Societe Generale strategists note that the recent USD/KRW bounce stalled around 1390 and the pair is now testing the lower end of its consolidation, suggesting the broader downtrend may resume. A brief rebound could face resistance at 1367/1372, with downside objectives at 1318 and 1303/1297 if the pair fails to clear those levels.
Bounce fades with fresh downside objectives
"Separately, the KRW rallied to 1333, strongest level vs USD in two years on the back of broad USD retreat, pullback in oil and corporate dollar sales."
"USD/KRW bounce petered out around 1390 and is now challenging the lower limit of its recent consolidation, suggesting that the downtrend may be resuming."
"If a brief rebound materializes, the high achieved earlier this month at 1367/1372 could act as an important hurdle."
"An inability to overcome this resistance may result in a continuation of the decline."
"The next objectives are located at projections of 1318 and 1303/1297."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy
Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized
BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review
Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).
4 Big Bank Earnings to Watch This Week as Wall Street Turns Bullish
